Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter
MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click: www.youtube.com/msviewsandnews
Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Saturday, August 8, 2015
The American Academy of Neurology (AAN) is the world’s largest association of neurologists and neuroscience professionals. Neurologists are doctors who identify and treat diseases of the brain and nervous system.
The AAN is dedicated to promoting the highest quality patient-centered neurologic care. Experts from the AAN carefully reviewed the available scientific studies on CAM therapies for MS. The following information* is based on evidence from those studies.
The information summarizes the main findings of the 2014 AAN guideline on CAM in MS. To read the full guideline, visit http://tinyurl.com/ogtxdtz
However, the desire to be productive and keep working remains the same. The good news is that it is very possible to continue to work after a diagnosis of MS, but it is also helpful to be aware of the options you have when MS symptoms start to make things more difficult to manage.
Talking About MS Symptoms in the Workplace
One of the first difficult decisions someone newly diagnosed with multiple sclerosislearns is which people to tell about your MS and how much to tell them, says Nicholas LaRocca, PhD, vice president of health care delivery and policy research at the National Multiple Sclerosis Society.
Continue reading from #EverydayHealth
Click here to read these tips
“MSPrecise scoring is a powerful approach to aid clinicians in this task,” said Colin Bier, Chief Development Officer of Amarantus Diagnostics, in information provided to Multiple Sclerosis News Today. “In this study completed in 2013 and now reported in ‘GENE,’ there is an overall MSPrecise accuracy of 84% in identifying relapsing-remitting multiple sclerosis (RRMS) patients or patients that will develop RRMS, which represents a huge benefit to physicians.”
Altered Immune Cells in Relapsing Remitting Multiple Sclerosis Patients Cause Reduced Immune Capacity
Click here to continue reading
Friday, August 7, 2015
Thursday, August 6, 2015
- Nature Reviews Neurology
- Published online
This is a topic that so many of us with MS hardly know anything about, with regards to the Why, the What and so much more regarding Our Multiple Sclerosis.
Take a look at this topic showing by clicking this link or clicking on the image shown above.
Information for this topic and as shown above, was provided by Ben Thrower, MD
Please review then share with others by providing them with this link
Medically Reviewed by The Healthline Medical Team on July 24, 2015
When you’re going through something that your friends and family don’t understand, they don’t always know what to say. Sometimes it can feel like they’re being insensitive, uncaring, or downright rude.
MS isn’t easier on the young, nor is it more likely to get better. Imagine being in the prime of your life and dealing with unpredictable neurological symptoms. The realization of having a chronic illness at a young age may be overwhelming. It’s better to simply offer your emotional and practical support.
Wednesday, August 5, 2015
Guest Speaker: Jenifer Patterson, APRN
Guest Speaker, Tricia Pagnotta, ARNP-C, MSN
1. Eat for optimal health.
2. Commit to regular exercise.
3. Address sleep issues.
4. Customize your environment.
Can Do Multiple Sclerosis Launches Online Photo Pledge Campaign to Ignite “Can Do” Spirit in People with MS and Their Loved Ones
Gilenya (fingolimod): Drug Safety Communication - FDA Warns About Cases of Rare Brain Infection (PML)
BACKGROUND: Gilenya is an immunomodulator shown to benefit patients with relapsing forms of MS. This type of MS causes attacks or relapses, which are periods of time when symptoms get worse. Immunomodulators alter the immune system to reduce inflammation. PML is a rare and serious brain infection caused by the John Cunningham (JC) virus. The JC virus is a common virus that is harmless in most people but can cause PML in some patients who have weakened immune systems, including those taking immunosuppressant drugs.
In an August 2013 Drug Safety Communication, FDA reported that a patient developed PML after taking Gilenya. PML could not be conclusively linked to Gilenya in this case because prior to Gilenya treatment the patient had been treated with an immunosuppressant drug that can cause PML and during Gilenya treatment the patient had received multiple courses of intravenous corticosteroids, which can weaken the immune system.
RECOMMENDATION: Patients taking Gilenya should contact their health care professionals right away if they experience symptoms such as new or worsening weakness; increased trouble using their arms or legs; or changes in thinking, eyesight, strength, or balance. Patients should not stop taking Gilenya without first discussing it with their health care professionals. Health care professionals should stop Gilenya and perform a diagnostic evaluation if PML is suspected. See the Drug Safety Communication for additional recommendations.